These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Novel anti-inflammatory therapies for the treatment of atherosclerosis. Khan R; Spagnoli V; Tardif JC; L'Allier PL Atherosclerosis; 2015 Jun; 240(2):497-509. PubMed ID: 25917947 [TBL] [Abstract][Full Text] [Related]
23. Potential of anti-inflammatory agents for treatment of atherosclerosis. Chistiakov DA; Melnichenko AA; Grechko AV; Myasoedova VA; Orekhov AN Exp Mol Pathol; 2018 Apr; 104(2):114-124. PubMed ID: 29378168 [TBL] [Abstract][Full Text] [Related]
24. Effect of interleukin 1β inhibition in cardiovascular disease. Qamar A; Rader DJ Curr Opin Lipidol; 2012 Dec; 23(6):548-53. PubMed ID: 23069985 [TBL] [Abstract][Full Text] [Related]
25. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation. Gu Y; Lee HM; Sorsa T; Salminen A; Ryan ME; Slepian MJ; Golub LM Pharmacol Res; 2011 Dec; 64(6):573-9. PubMed ID: 21771657 [TBL] [Abstract][Full Text] [Related]
26. Extracellular vesicles as new pharmacological targets to treat atherosclerosis. Yin M; Loyer X; Boulanger CM Eur J Pharmacol; 2015 Sep; 763(Pt A):90-103. PubMed ID: 26142082 [TBL] [Abstract][Full Text] [Related]
27. Targeting the Immune System in Atherosclerosis: JACC State-of-the-Art Review. Zhao TX; Mallat Z J Am Coll Cardiol; 2019 Apr; 73(13):1691-1706. PubMed ID: 30947923 [TBL] [Abstract][Full Text] [Related]
31. T cell-based therapies for atherosclerosis. Ketelhuth DF; Gisterå A; Johansson DK; Hansson GK Curr Pharm Des; 2013; 19(33):5850-8. PubMed ID: 23438952 [TBL] [Abstract][Full Text] [Related]
32. Anti-inflammatory Strategies in Atherosclerosis. Bugger H; Zirlik A Hamostaseologie; 2021 Dec; 41(6):433-442. PubMed ID: 34942656 [TBL] [Abstract][Full Text] [Related]
33. Immunomodulation Therapies for Atherosclerosis: The Past, the Present, and the Future. Lecis D; Massaro G; Benedetto D; Di Luozzo M; Russo G; Mauriello A; Federici M; Sangiorgi GM Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446157 [TBL] [Abstract][Full Text] [Related]
34. Update on selective treatments targeting neutrophilic inflammation in atherogenesis and atherothrombosis. Gomes Quinderé AL; Benevides NM; Carbone F; Mach F; Vuilleumier N; Montecucco F Thromb Haemost; 2014 Apr; 111(4):634-46. PubMed ID: 24285257 [TBL] [Abstract][Full Text] [Related]
35. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis. Hafiane A; Daskalopoulou SS Pharmacol Res; 2022 Apr; 178():106157. PubMed ID: 35257900 [TBL] [Abstract][Full Text] [Related]
36. Nanomedicine-based strategies for treatment of atherosclerosis. Schiener M; Hossann M; Viola JR; Ortega-Gomez A; Weber C; Lauber K; Lindner LH; Soehnlein O Trends Mol Med; 2014 May; 20(5):271-81. PubMed ID: 24594264 [TBL] [Abstract][Full Text] [Related]
39. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease. Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900 [TBL] [Abstract][Full Text] [Related]
40. Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications. Montarello NJ; Nguyen MT; Wong DTL; Nicholls SJ; Psaltis PJ Cardiovasc Drugs Ther; 2022 Apr; 36(2):347-362. PubMed ID: 33170943 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]